These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36830860)

  • 1. A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy.
    Parisi R; Shah H; Shear NH; Ziv M; Markova A; Dodiuk-Gad RP
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy.
    Deutsch A; Leboeuf NR; Lacouture ME; McLellan BN
    Am Soc Clin Oncol Educ Book; 2020 May; 40():485-500. PubMed ID: 32421446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review.
    Liu LY; Teng JMC; Spunt SL; Strelo JL; Kwong BY; Zaba LC
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29346. PubMed ID: 34569142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.
    Kuo AM; Markova A
    Front Med (Lausanne); 2022; 9():898790. PubMed ID: 35770005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature.
    Belzer A; Pach JJ; Valido K; Leventhal JS
    Am J Clin Dermatol; 2024 May; 25(3):435-445. PubMed ID: 38366030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucocutaneous adverse events to immune checkpoint inhibitors.
    Muhaj F; Karri PV; Moody W; Brown A; Patel AB
    Front Allergy; 2023; 4():1147513. PubMed ID: 36938327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.
    Gnanendran SS; Turner LM; Miller JA; Hwang SJE; Miller AC
    Curr Treat Options Oncol; 2020 Mar; 21(4):29. PubMed ID: 32193712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.
    Wang X; Suppa M; Bruderer P; Sirtaine N; Aspeslagh S; Kerger J
    Case Rep Oncol; 2021; 14(2):861-867. PubMed ID: 34248552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
    JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.
    Pospischil I; Hoetzenecker W
    J Dtsch Dermatol Ges; 2021 Nov; 19(11):1621-1643. PubMed ID: 34811916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
    Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL
    J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
    Apalla Z; Nikolaou V; Fattore D; Fabbrocini G; Freites-Martinez A; Sollena P; Lacouture M; Kraehenbuehl L; Stratigos A; Peris K; Lazaridou E; Richert B; Vigarios E; Riganti J; Baroudjian B; Filoni A; Dodiuk-Gad R; Lebbé C; Sibaud V
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):332-350. PubMed ID: 34910332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.
    Park BC; Jung S; Chen ST; Dewan AK; Johnson DB
    Am J Clin Dermatol; 2022 Sep; 23(5):707-717. PubMed ID: 35708849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
    Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
    Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.